<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03407404</url>
  </required_header>
  <id_info>
    <org_study_id>2015/HD07/1275U</org_study_id>
    <nct_id>NCT03407404</nct_id>
  </id_info>
  <brief_title>Comparing Clinical Outcomes Between Ketamine-midazolam and Morphine-midazolam for Continous Sedation in ICU Patients.</brief_title>
  <acronym>KeMiMof</acronym>
  <official_title>Ketamine-Midazolam Versus Morphine-Midazolam for Continous Patient Sedation in Intensive Care Units in Uganda. A Randomised Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Makerere University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>THRiVE</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Makerere University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, double-blinded, multicenter randomized control trial. All critically ill
      patients above 12 years of age requiring continuous sedation for &gt;24hrs in the ICU will be
      screened and those meeting selection criteria (and consented) will be enrolled into the
      study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      165 participants shall be consecutively randomized into either sedation with
      ketamine-midazolam or morphine-midazolam group using a block sequence technique; group
      concealed in brown envelopes. Blinding will be at patient/next of kin level as well as
      investigator/data collector level.

      Enrolled subjects shall be followed up for treatment history, co-morbidities and related data
      will be collected, results analyzed and study findings will be availed to ICU physicians and
      Ministry of health to guide treatment considerations and for health care planning.

      Data shall be collected using a standardized questionnaire by trained research assistants. It
      will be double entered into Epidata and exported to STATA version 12.0 for analysis.
      Continuous variables will be expressed as means and standard deviations, while categorical
      data will be expressed as frequencies with their respective percentages. Linear regression
      and logistic regression used to analyse primary outcomes, as well as multivariate analysis to
      detect associations.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2017</start_date>
  <completion_date type="Anticipated">June 15, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 22, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomized to either receive ketamine-midazolam or morphine-midazolam for continous sedation at enrollment, then followed up for outcomes.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Drugs will be premixed and coded for ketamine-midazolam or morphine-midazolam. The colorless drug mixture shall be provided to the attending physician to start the infusion at 2ml/hour and to be titrated to the desired level of sedation.
The investigator and participant will be unaware of which group a certain patient is under.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>duration of mechanical ventilation</measure>
    <time_frame>14 days</time_frame>
    <description>in hours from start of mechanical ventialtion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence of hypotension</measure>
    <time_frame>14 days</time_frame>
    <description>incidence of hypotension requiring vasopressor support.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence of delirium</measure>
    <time_frame>14 days</time_frame>
    <description>assessed daily with the CAM-ICU score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>14 days</time_frame>
    <description>length of stay in the intensive care unit from enrollment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality rate</measure>
    <time_frame>within 14 days</time_frame>
    <description>number of deaths in each study arm</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">165</enrollment>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>Ketamine-midazolam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continous intravenous sedation with a colorless drug mixture in 50ml syringe containing 900mg ketamine and 36mg midazolam.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine-Midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continous intravenous sedation with a colourless drug mixture in 50ml syringes containing 54mg morphine and 36mg midazolam.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Ketamine-Midazolam</intervention_name>
    <description>Continous intravenous sedation with 36mg of Midazolam and 900mg of Ketamine mixed in 50ml syringes as long as patient still requires sedation.</description>
    <arm_group_label>Ketamine-midazolam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Morphine -Midazolam</intervention_name>
    <description>Continous intravenous sedation with 54mg of Morphine Sulphate and 36mg of midazolam mixed in 50ml syringes as long as participant still requires sedation.</description>
    <arm_group_label>Morphine-Midazolam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt;12years of age.

          2. Anticipated need for sedation for &gt;24hours.

        Exclusion Criteria:

          1. Hypertensive crisis i.e. sustained SBP &gt;200mmHg/DBP&gt;110mmHg

          2. Status epilepticus

          3. Ischemic heart disease and severe LV dysfunction

          4. Persistent tachyarrythmias

          5. History of mental illness

          6. Hypersensitivity to ketamine, morphine or midazolam.

          7. Tetanus -due to the muscle rigidity that may be caused by ketamine. Reasons for
             exclusions 1 to 4; Ketamine stimulates the sympathetic nervous system causing
             transient increase in myocardial work and blood pressure and has psychoactive effects
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Namata, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Makerere University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine Namata, MBChB</last_name>
    <phone>0772079499</phone>
    <email>chremma13@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arthur Kwizera, MMed</last_name>
    <phone>0772897171</phone>
    <email>kwizera.arthur@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mulago National Referral Hospital ICU</name>
      <address>
        <city>Kampala</city>
        <state>Central</state>
        <zip>256</zip>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martha Alupo, Nursing</last_name>
      <phone>0772847662</phone>
      <email>alupomartha@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Christine Namata, MBChB</last_name>
      <phone>0772079499</phone>
      <email>chremma13@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2017</study_first_submitted>
  <study_first_submitted_qc>January 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2018</study_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

